Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73% Market Closed
Market Cap: 457.1m GBX
Have any thoughts about
Amryt Pharma Holdings Ltd?
Write Note

Intrinsic Value

AMYT price has not been updated for more than 1 year. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the intrinsic value of AMYT.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AMYT Intrinsic Value
Not Available
Base Case Scenario
How do you feel about AMYT?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Amryt Pharma Holdings Ltd

Provide an overview of the primary business activities
of Amryt Pharma Holdings Ltd.

What unique competitive advantages
does Amryt Pharma Holdings Ltd hold over its rivals?

What risks and challenges
does Amryt Pharma Holdings Ltd face in the near future?

Show all valuation multiples
for Amryt Pharma Holdings Ltd.

Provide P/S
for Amryt Pharma Holdings Ltd.

Provide P/E
for Amryt Pharma Holdings Ltd.

Provide P/OCF
for Amryt Pharma Holdings Ltd.

Provide P/FCFE
for Amryt Pharma Holdings Ltd.

Provide P/B
for Amryt Pharma Holdings Ltd.

Provide EV/S
for Amryt Pharma Holdings Ltd.

Provide EV/GP
for Amryt Pharma Holdings Ltd.

Provide EV/EBITDA
for Amryt Pharma Holdings Ltd.

Provide EV/EBIT
for Amryt Pharma Holdings Ltd.

Provide EV/OCF
for Amryt Pharma Holdings Ltd.

Provide EV/FCFF
for Amryt Pharma Holdings Ltd.

Provide EV/IC
for Amryt Pharma Holdings Ltd.

Show me price targets
for Amryt Pharma Holdings Ltd made by professional analysts.

What are the Revenue projections
for Amryt Pharma Holdings Ltd?

How accurate were the past Revenue estimates
for Amryt Pharma Holdings Ltd?

What are the Net Income projections
for Amryt Pharma Holdings Ltd?

How accurate were the past Net Income estimates
for Amryt Pharma Holdings Ltd?

What are the EPS projections
for Amryt Pharma Holdings Ltd?

How accurate were the past EPS estimates
for Amryt Pharma Holdings Ltd?

What are the EBIT projections
for Amryt Pharma Holdings Ltd?

How accurate were the past EBIT estimates
for Amryt Pharma Holdings Ltd?

Compare the revenue forecasts
for Amryt Pharma Holdings Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amryt Pharma Holdings Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amryt Pharma Holdings Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amryt Pharma Holdings Ltd compared to its peers.

Compare the P/E ratios
of Amryt Pharma Holdings Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Amryt Pharma Holdings Ltd with its peers.

Analyze the financial leverage
of Amryt Pharma Holdings Ltd compared to its main competitors.

Show all profitability ratios
for Amryt Pharma Holdings Ltd.

Provide ROE
for Amryt Pharma Holdings Ltd.

Provide ROA
for Amryt Pharma Holdings Ltd.

Provide ROIC
for Amryt Pharma Holdings Ltd.

Provide ROCE
for Amryt Pharma Holdings Ltd.

Provide Gross Margin
for Amryt Pharma Holdings Ltd.

Provide Operating Margin
for Amryt Pharma Holdings Ltd.

Provide Net Margin
for Amryt Pharma Holdings Ltd.

Provide FCF Margin
for Amryt Pharma Holdings Ltd.

Show all solvency ratios
for Amryt Pharma Holdings Ltd.

Provide D/E Ratio
for Amryt Pharma Holdings Ltd.

Provide D/A Ratio
for Amryt Pharma Holdings Ltd.

Provide Interest Coverage Ratio
for Amryt Pharma Holdings Ltd.

Provide Altman Z-Score Ratio
for Amryt Pharma Holdings Ltd.

Provide Quick Ratio
for Amryt Pharma Holdings Ltd.

Provide Current Ratio
for Amryt Pharma Holdings Ltd.

Provide Cash Ratio
for Amryt Pharma Holdings Ltd.

What is the historical Revenue growth
over the last 5 years for Amryt Pharma Holdings Ltd?

What is the historical Net Income growth
over the last 5 years for Amryt Pharma Holdings Ltd?

What is the current Free Cash Flow
of Amryt Pharma Holdings Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Amryt Pharma Holdings Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amryt Pharma Holdings Ltd

Current Assets 276.8m
Cash & Short-Term Investments 123.2m
Receivables 52.8m
Other Current Assets 100.8m
Non-Current Assets 578.7m
PP&E 8.4m
Intangibles 488.7m
Other Non-Current Assets 81.5m
Current Liabilities 153.8m
Other Current Liabilities 153.8m
Non-Current Liabilities 395.6m
Long-Term Debt 200.6m
Other Non-Current Liabilities 195m
Efficiency

Earnings Waterfall
Amryt Pharma Holdings Ltd

Revenue
210.2m USD
Cost of Revenue
-106.8m USD
Gross Profit
103.4m USD
Operating Expenses
-126.8m USD
Operating Income
-23.3m USD
Other Expenses
-64.2m USD
Net Income
-87.5m USD

Free Cash Flow Analysis
Amryt Pharma Holdings Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AMYT Profitability Score
Profitability Due Diligence

Amryt Pharma Holdings Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
Declining ROE
26/100
Profitability
Score

Amryt Pharma Holdings Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

AMYT Solvency Score
Solvency Due Diligence

Amryt Pharma Holdings Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
37/100
Solvency
Score

Amryt Pharma Holdings Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMYT Price Targets Summary
Amryt Pharma Holdings Ltd

There are no price targets for AMYT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AMYT?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for AMYT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

453.2m GBP

Dividend Yield

0%

Description

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.

Contact

London
Ivybridge House, 1 Adam Street
+442034155730
www.amrytpharma.com

IPO

2007-04-27

Employees

99

Officers

CEO & Director
Dr. Joseph A. Wiley
CFO, COO & Company Sec.
Mr. Rory P. Nealon
Sr. VP & Global Chief Compliance Officer
Ms. Elizabeth Varki Jobes J.D.
Gen. Counsel
Mr. John McEvoy
VP of Global Marketing
Mr. Stephen Joyce
Head of HR
Ms. Julie Eastwood
Show More
Head of Regulatory Affairs
Ms. Derval O'Carroll
Head of Manufacturing Supply Chain
Mr. Gerry Gilligan
Chief Medical Officer
Dr. Mark Sumeray
Head of Medical Affairs
Dr. Helen Phillips
Show Less

See Also

Discover More